Luteinizing hormone Not Yet Recruiting Phase 3 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03488810Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
NCT04136353Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate